Companies House 09415363 2025-02-01 2025-02-01 2024-02-02 false iso4217:GBP xbrli:pure 09415363 2023-02-02 2024-02-01 09415363 2025-02-01 09415363 2024-02-02 2025-02-01 09415363 2024-02-01 09415363 curr:PoundSterling 2024-02-02 2025-02-01 09415363 uk-bus:CompanyLimitedByGuarantee 2024-02-02 2025-02-01 09415363 uk-bus:FRS102 2024-02-02 2025-02-01 09415363 uk-bus:AuditExempt-NoAccountantsReport 2024-02-02 2025-02-01 09415363 uk-bus:FullAccounts 2024-02-02 2025-02-01 09415363 uk-bus:RegisteredOffice 2024-02-02 2025-02-01 09415363 uk-bus:Director1 2024-02-02 2025-02-01 09415363 uk-bus:Director2 2024-02-02 2025-02-01 09415363 uk-bus:Director3 2024-02-02 2025-02-01 09415363 uk-bus:Director4 2024-02-02 2025-02-01 09415363 uk-bus:Director5 2024-02-02 2025-02-01 09415363 uk-bus:Director6 2024-02-02 2025-02-01 09415363 uk-bus:Director7 2024-02-02 2025-02-01 09415363 uk-bus:Director8 2024-02-02 2025-02-01 09415363 uk-bus:Director9 2024-02-02 2025-02-01 09415363 uk-bus:Director10 2024-02-02 2025-02-01 09415363 uk-bus:Director11 2024-02-02 2025-02-01 09415363 uk-bus:Director12 2024-02-02 2025-02-01 09415363 uk-bus:Director13 2024-02-02 2025-02-01 09415363 uk-bus:Director14 2024-02-02 2025-02-01 09415363 uk-bus:Director15 2024-02-02 2025-02-01 09415363 uk-bus:Director16 2024-02-02 2025-02-01 09415363 uk-bus:Director17 2024-02-02 2025-02-01 09415363 uk-bus:Director18 2024-02-02 2025-02-01 09415363 uk-bus:Director19 2024-02-02 2025-02-01 09415363 uk-bus:Director20 2024-02-02 2025-02-01 09415363 uk-bus:Director21 2024-02-02 2025-02-01 09415363 uk-bus:CompanySecretary1 2024-02-02 2025-02-01 09415363 core:AfterOneYear 2025-02-01 09415363 core:AfterOneYear 2024-02-01 09415363 core:WithinOneYear 2025-02-01 09415363 core:WithinOneYear 2024-02-01 09415363 core:WithinOneYear 2024-02-02 2025-02-01 09415363 core:AfterOneYear 2025-02-01 09415363 core:AfterOneYear 2024-02-01 09415363 core:AfterOneYear 2024-02-02 2025-02-01 09415363 core:ShareCapital 2025-02-01 09415363 core:ShareCapital 2024-02-01 09415363 core:SharePremium 2025-02-01 09415363 core:SharePremium 2024-02-01 09415363 core:OtherReservesSubtotal 2025-02-01 09415363 core:OtherReservesSubtotal 2024-02-01 09415363 core:RevaluationReserve 2025-02-01 09415363 core:RevaluationReserve 2024-02-01 09415363 core:RetainedEarningsAccumulatedLosses 2025-02-01 09415363 core:RetainedEarningsAccumulatedLosses 2024-02-01 09415363 1 2024-02-02 2025-02-01 09415363 2 2024-02-02 2025-02-01 09415363 3 2024-02-02 2025-02-01 09415363 core:LandBuildings 2024-02-02 2025-02-01 09415363 core:LandBuildings 2025-02-01 09415363 core:LandBuildings 2023-02-02 2024-02-01 09415363 core:LandBuildings 2024-02-01 09415363 core:PlantMachinery 2024-02-02 2025-02-01 09415363 core:PlantMachinery 2025-02-01 09415363 core:PlantMachinery 2023-02-02 2024-02-01 09415363 core:PlantMachinery 2024-02-01 09415363 core:FurnitureFittingsToolsEquipment 2024-02-02 2025-02-01 09415363 core:FurnitureFittingsToolsEquipment 2025-02-01 09415363 core:FurnitureFittingsToolsEquipment 2023-02-02 2024-02-01 09415363 core:FurnitureFittingsToolsEquipment 2024-02-01 09415363 core:OfficeEquipment 2024-02-02 2025-02-01 09415363 core:OfficeEquipment 2025-02-01 09415363 core:OfficeEquipment 2023-02-02 2024-02-01 09415363 core:OfficeEquipment 2024-02-01 09415363 core:Vehicles 2024-02-02 2025-02-01 09415363 core:Vehicles 2025-02-01 09415363 core:Vehicles 2023-02-02 2024-02-01 09415363 core:Vehicles 2024-02-01 09415363 core:NetGoodwill 2024-02-02 2025-02-01 09415363 core:NetGoodwill 2025-02-01 09415363 core:NetGoodwill 2023-02-02 2024-02-01 09415363 core:NetGoodwill 2024-02-01 09415363 core:IntangibleAssetsOtherThanGoodwill 2024-02-02 2025-02-01 09415363 core:IntangibleAssetsOtherThanGoodwill 2025-02-01 09415363 core:IntangibleAssetsOtherThanGoodwill 2023-02-02 2024-02-01 09415363 core:IntangibleAssetsOtherThanGoodwill 2024-02-01

# FELLSIDE THERAPIES CIC

## Company limited by guarantee

## Company Registration Number:
09415363 (England and Wales)

## Unaudited statutory accounts for the year ended 1 February 2025

## Period of accounts

## Start date: 2 February 2024

## End date: 1 February 2025

# FELLSIDE THERAPIES CIC

## Contents of the Financial Statements

for the Period Ended 1 February 2025

Profit and loss |
Balance sheet |
Additional notes |
Community Interest Report |

# FELLSIDE THERAPIES CIC

## Profit And Loss Account

for the Period Ended 1 February 2025

| 2025 | 2024
--- | --- | ---
| £ | £
Turnover: | 3,860 | 2,850
Cost of sales: | 0 | 0
Gross profit(or loss): | 3,860 | 2,850
Distribution costs: | 0 | 0
Administrative expenses: | ( 3,886 ) | ( 2,995 )
Other operating income: | 0 | 0
Operating profit(or loss): | (26) | (145)
Interest receivable and similar income: | 0 | 0
Interest payable and similar charges: | 0 | 0
Profit(or loss) before tax: | (26) | (145)
Tax: | 0 | 0
Profit(or loss) for the financial year: | (26) | (145)

# FELLSIDE THERAPIES CIC

## Balance sheet

As at 1 February 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Fixed assets
Intangible assets: |  | 0 | 0
Tangible assets: |  | 0 | 0
Investments: |  | 0 | 0
Total fixed assets: |  | 0 | 0
Current assets
Stocks: |  | 0 | 0
Debtors: |  | 0 | 0
Cash at bank and in hand: |  | 3,860 | 2,850
Investments: |  | 0 | 0
Total current assets: |  | 3,860 | 2,850
Prepayments and accrued income: |  | 0 | 0
Creditors: amounts falling due within one year: |  | 0 | 0
Net current assets (liabilities): |  | 3,860 | 2,850
Total assets less current liabilities: |  | 3,860 | 2,850
Creditors: amounts falling due after more than one year: |  | 0 | 0
Provision for liabilities: |  | 0 | 0
Accruals and deferred income: |  | 0 | 0
Total net assets (liabilities): |  | 3,860 | 2,850
Members' funds
Profit and loss account: |  | 3,860 | 2,850
Total members' funds: |  | 3,860 | 2,850

The notes form part of these financial statements

# FELLSIDE THERAPIES CIC

## Balance sheet statements

For the year ending 1 February 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 19 June 2025
and signed on behalf of the board by:

Name: Julie Price
Status: Director

The notes form part of these financial statements

# FELLSIDE THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 1 February 2025

- ## 1. Accounting policies

  Basis of measurement and preparation

  These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

# FELLSIDE THERAPIES CIC

## Notes to the Financial Statements

for the Period Ended 1 February 2025

- ## 2. Employees

  | 2025 | 2024
  --- | --- | ---
  Average number of employees during the period | 0 | 0

# COMMUNITY INTEREST ANNUAL REPORT

### FELLSIDE THERAPIES CIC

### Company Number: 09415363 (England and Wales)

### Year Ending: 1 February 2025

Company activities and impact

The company provides people in the Eden Valley and elsewhere in northern England, in particular people with mental health issues and their families, friends and supporters with - counselling and therapy services - other wellbeing oriented services and activities - increased awareness of mental health issues. During the financial year 2024–2025, the company has provided benefits to the community in the following ways - residents have been able to access local counselling services - patients from two GP surgeries in the Eden Valley received mental health support during breathing workshops - individuals have received confidential advice on mental health awareness.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
19 June 2025

And signed on behalf of the board by:
Name: Julie Price
Status: Director